Rna Diagnostics Inc. announced today that Dr. Matthew P. Goetz has been appointed to the company’s Clinical Advisory Board (CAB).

A newly published study provides further data showing Straticyte offers better predictive insight over histopathological dysplasia grading for oral potentially malignant lesion assessment.

KA Imaging, a 2016 CAAP Company, is one of the first three companies to receive funding via FACIT's new Prospects Oncology Fund.

The Biotech Showcase is an investor partnering conference devoted to offering private and public biotechnology and life sciences companies an opportunity to present to and meet with investors and pharma executives.  

Last week, the Government of Canada launched the Strategic Innovation Fund, a new $1.26-billion business investment program. 

The Health IT Canadian Technology Accelerator in the US is accepting applications for fall 2017.

The Canadian Technology Accelerator helps high-potential, high-growth Canadian technology SMEs seeking to expand to the US through a program of workshops, events, mentorship and business introductions.

BlueOceanNutraSciences Inc. (TSXV:BOC) announced that it has received a Natural Products Number (NPN) from Health Canada for its extended release Omega-3 astaxanthin shrimp oil tablets (“XR tablets”), the World’s first Omega-3 oils in XR tablet form.

The Company’s shrimp oil XR tablets were developed by its joint venture partner, CMAX Technologies Inc. (“CMAX”).

Stéphane Gagné, President and CEO of Ovensa Inc - a CAAP alumni - attended BIO 2017 and contributed this report on the value of the conference to Ontario’s life sciences industry.

ScarX Therapeutics, an OBIO CAAP program alumni, announced today it has completed enrollment for its initial human clinical trial of SCX-001, a first-of-its-kind topical treatment to significantly reduce surgical scarring.

Application deadline: August 10th, 2017 - APPLY HERE

Apply now if you are interested in meeting one-on-one with Forbion Capital Partners, after their "Investor Spotlight" presentation at JLabs on September 6th, 2017.

Application deadline: July 26, 2017 at 2:00pm EDT - APPLY HERE

One month left until the application deadline for the Postdoctoral Scholars 2017 program. 
Please share this message with all current postdoctoral researchers at your institution.

NOVADAQ Technologies Inc. (NASDAQ:NVDQ) (TSX:NDQ) the leading provider of proven comprehensive fluorescence imaging solutions that improve clinical outcomes and reduce healthcare costs in minimally invasive and open surgeries, today announced that it has entered into a definitive arrangement  with Stryker Corporation to acquire all of the issued and outstanding shares of NOVADAQ.

Suzanne was interviewed about her deep career in technology, military, non-profit, health and creative fields.

Rna Diagnostics announced the launch of an international prospective clinical trial to validate the RNA Disruption Assay™ (RDA™) as a tool for treatment management of primary breast cancer.

Proteorex Therapeutics Inc., a 2017 CAAP company, announced a research and development collaboration with Montreal-based Corbin Therapeutics.

Proteocyte Diagnostics hosted their first global Straticyte™ meeting at the 6th World Oral Cancer Congress of the International Academy of Oral Oncology (IAOO) in India  on May 18, 2017.

PanamericanWorld is a Canadian digital online magazine which reaches online communities throughout the Americas, in Spanish, English, and Portuguese.

Grand Challenges Canada, a platform supporting innovation in global health funded by the Government of Canada, has launched a new funding opportunity through its Stars in Global Health program: "Stars in Reproductive, Maternal, Newborn and Child Health (RMNCH)."

Sernova reports on active pharma collaboration, upcoming clinical trial and fertile BD pipeline to advance scale of diabetes and hemophilia programs

TORONTO, June 6, 2017 ‐ Lumira Capital, a leading North American healthcare venture capital firm, announced today that it has launched a new philanthropic initiative whereby the firm’s partners will donate a portion of their profit share from Lumira Capital IV L.P. to up to fifteen leading healthcare foundations in Canada.